BioSpace News Archive

ZENITH20 Phase 2 clinical trial amended to include new dosing regimens aimed at improving therapeutic index Management to host webcast and conference call today to review data and program strategy at 8:30 a.m. ET

IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended March 31, 2020.

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2020 after the market closes on Tuesday, May 5, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tu

Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in two upcoming investor conferences.

Comprehensive Turnkey System Based on Industry-Leading LabVantage LIMS Platform Allows Laboratories to Implement COVID-19 Biobanking, Testing and Research Almost Immediately

Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual Conference presented by Maxim Group on May 5, 2020. Ms. Johnson will be a member of the panel discussing non-antibiotic anti-infectives, scheduled from 10:30 a.m. to 12:00 p.m. Eastern Time. During the panel dis

The Company Easily Surpasses its Previous Monthly Record, of $14,607.91 in E-Commerce Sales, Posted During March 2020

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s Committee for Orphan Medicinal Products has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas.

SCYNEXIS, Inc. announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel discussion on fungal pathogens and the emerging treatment landscape at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020.